Skip to content

Study · Observational study · n = 406 · 2025

4 results

Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes.

Pérez-Velasco MA, Bernal-López MR, Trenas A, Ricci M, López-Carmona MD, García de Lucas MD, Gómez-Huelgas R, Pérez-Belmonte LM

Medicina clinica3 Jun 2025Cited by 2 (Europe PMC)

PMID40466271 (opens in a new tab)DOI10.1016/j.medcli.2025.107019 (opens in a new tab)PepBankPUB-40466271
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In matched patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes, a primary outcome event (KCCQ difference of 5 points or more) occurred in 60.6% on once-weekly semaglutide versus 17.7% of controls.

    In plain wordsIn patients with heart failure, obesity and type 2 diabetes, more semaglutide users than controls had a clear gain in heart failure symptom score.

    Peptide
    Semaglutide
    Outcome
    IncreaseHeart failure status (KCCQ total symptom score difference of 5 points or more)
    Study

    n = 406

    Comparator
    Patients not treated with GLP-1 receptor agonists (propensity-matched)
    Analysis
    Primary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.00 mg once weeklyAs given in this study (human).

    Measurements

    Primary outcome event
    60.6%
    semaglutide
    Primary outcome event
    17.7%
    control
    Odds ratio
    3.99 ratio
    semaglutide versus control

    Source sentences

    Summary
    A primary outcome event occurred in 123 patients (60.6%) in the Sema-Preserved Group and 36 (17.7%) in the Control-Preserved Group (odds ratio: 3.99; 95% confidence interval: 1.69-6.28; p<0.01)
    2 context sentences
    Summary · context
    This prospective, real-world study included patients with heart heart failure with preserved ejection fraction, obesity and type 2 diabetes treated with once-weekly 1.00mg semaglutide (Sema-Preserved Group) and patients not treated with glucagon-like peptide-1 receptor agonists (Control-Preserved Group).
    Summary · context
    After matching, 203 patients were included in each group.
  2. 02HumanObservational studyEfficacy outcome

    In matched patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes, mean body weight change was -12.9 kg with semaglutide versus -2.5 kg in controls.

    In plain wordsIn patients with heart failure, obesity and type 2 diabetes, semaglutide users lost more weight than controls.

    Peptide
    Semaglutide
    Outcome
    DecreaseChange in body weight at 24 months
    Study

    n = 406

    Comparator
    Patients not treated with GLP-1 receptor agonists (propensity-matched)
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.00 mg once weekly · 24 monthsAs given in this study (human).

    Measurements

    Mean change in body weight
    −12.9 kg
    semaglutide
    Mean change in body weight
    −2.5 kg
    control

    Source sentences

    Summary
    the mean change in body weight was -12.9±4.2kg in patients with semaglutide and -2.5±1.1kg in control patients (p<0.01).
    2 context sentences
    Summary · context
    This prospective, real-world study included patients with heart heart failure with preserved ejection fraction, obesity and type 2 diabetes treated with once-weekly 1.00mg semaglutide (Sema-Preserved Group) and patients not treated with glucagon-like peptide-1 receptor agonists (Control-Preserved Group).
    Summary · context
    After matching, 203 patients were included in each group.
  3. 03HumanObservational studyEfficacy outcome

    In matched patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes, semaglutide was associated with significantly fewer heart failure events than control.

    In plain wordsIn patients with heart failure, obesity and type 2 diabetes, semaglutide use was linked to fewer heart failure events than in controls.

    Peptide
    Semaglutide
    Outcome
    DecreaseHeart failure events
    Study

    n = 406

    Comparator
    Patients not treated with GLP-1 receptor agonists (propensity-matched)
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1.00 mg once weeklyAs given in this study (human).

    Source sentences

    Summary
    There were also significant declines in the heart failure events, and in all-cause hospitalizations.
    2 context sentences
    Summary · context
    This prospective, real-world study included patients with heart heart failure with preserved ejection fraction, obesity and type 2 diabetes treated with once-weekly 1.00mg semaglutide (Sema-Preserved Group) and patients not treated with glucagon-like peptide-1 receptor agonists (Control-Preserved Group).
    Summary · context
    After matching, 203 patients were included in each group.
  4. 04HumanObservational studyEfficacy outcome

    In matched patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes, semaglutide was associated with significantly fewer all-cause hospitalizations than control.

    In plain wordsIn patients with heart failure, obesity and type 2 diabetes, semaglutide use was linked to fewer hospital stays than in controls.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause hospitalizations
    Study

    n = 406

    Comparator
    Patients not treated with GLP-1 receptor agonists (propensity-matched)
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1.00 mg once weeklyAs given in this study (human).

    Source sentences

    Summary
    There were also significant declines in the heart failure events, and in all-cause hospitalizations.
    2 context sentences
    Summary · context
    This prospective, real-world study included patients with heart heart failure with preserved ejection fraction, obesity and type 2 diabetes treated with once-weekly 1.00mg semaglutide (Sema-Preserved Group) and patients not treated with glucagon-like peptide-1 receptor agonists (Control-Preserved Group).
    Summary · context
    After matching, 203 patients were included in each group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.